Nitrogen mustard compounds and prodrugs therefor

   
   

This invention pertains to nitrogen mustard compounds (Formula (II)) and prodrugs therefor (Formula (I)), methods for their preparation, pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in therapy and treatment, for example, of cancer, wherein: R.sup.1 and R.sup.2 are independently --Cl, --Br, --I, --OSO.sub.2 CH.sub.3, or --OSO.sub.2 Ph; R.sup.1a, R.sup.2a, R.sup.1b, and R.sup.2b are independently --H, a C.sub.1-4 alkyl group, or a C.sub.1-4 haloalkyl group; R.sup.3 is --F, --Cl, --Br, --I, --OCHF.sub.2, --C.ident.CH, --OCF.sub.3, --CH.sub.3, --CF.sub.3, --SF.sub.5, --SCF.sub.3, or --CF.sub.2 CF.sub.3 ; R.sup.4 is --H or as defined for R.sup.3-, R.sup.5 is --H or --F; R.sup.7 is --H, --C(CH.sub.3).sub.3, or --CH.sub.2 --CH--CH.sub.2 ; Z is --CH.sub.2 --T--W; T is --CH.sub.2 --, --O--, --S--, --(S.dbd.O)--, or --(SO.sub.2)--; W is one of: (1) --COOH; (2)--(C.dbd.O)OR.sup.8 ; (3) --(C.dbd.O)NR.sup.9 R.sup.9 ; (4) --SO.sub.2 NHR.sup.10-, (5) SO.sub.2 OR.sup.11 ; (6)--PO.sub.3 R.sup.11 R.sup.11 ; (7) a tetrazol-5-yl group; (8) --CONH--SO.sub.2 R.sup.12 ; and, (9)-M-Het. ##STR1##

Deze uitvinding behoort tot de samenstellingen van de stikstofmosterd (Formule (II)) en prodrugs daarvoor (Formule (I)), methodes voor hun voorbereiding, farmaceutische samenstellingen bestaand uit dergelijke samenstellingen, en het gebruik van dergelijke samenstellingen en samenstellingen, allebei in vitro en in vivo, in therapie en behandeling, bijvoorbeeld, van kanker, waarin: R.sup.1 en R.sup.2 zijn onafhankelijk cl, --Br, ii, -- OSO.sub.2 CH.sub.3, of -- PH OSO.sub.2; R.sup.1a, R.sup.2a, R.sup.1b, En R.sup.2b zijn onafhankelijk h, een alkyl groep c.sub.1-4, of een c.sub.1-4 haloalkylgroep; R.sup.3 is FF, cl, --Br, ii, -- OCHF.sub.2, -- C.ident.CH, -- OCF.sub.3, -- CH.sub.3, -- CF.sub.3, -- SF.sub.5, -- SCF.sub.3, of -- CF.sub.2 CF.sub.3; R.sup.4 is h of zoals bepaald voor R.sup.3 -, is R.sup.5 h of FF; R.sup.7 is h, -- C(CH.sub.3).sub.3, of -- CH.sub.2 -- CH -- CH.sub.2; Z is -- CH.sub.2 -- T -- W; T is -- CH.sub.2 --, o --, --S --, -- (S.dbd.O) - -, of -- (SO.sub.2) - -; W is één van: (1) -- COOH; (2) -- (C.dbd.O)OR.sup.8; (3) -- (C.dbd.O)NR.sup.9 R.sup.9; (4) -- SO.sub.2 NHR.sup.10 -, (5) SO.sub.2 OR.sup.11; (6) -- PO.sub.3 R.sup.11 R.sup.11; (7) een groep tetrazol-5; (8) -- CONH -- SO.sub.2 R.sup.12; en, (9)-m-het. ## STR1 ##

 
Web www.patentalert.com

< Sodium-hydrogen exchanger type 1 inhibitor

< Methods and apparatus for diagnostic multispectral digital imaging

> Fluid handling layers made from foam and absorbent articles containing same

> Polypeptide having water channel activity and DNA sequence

~ 00160